Assessment of Efficacy of AZD2281 in Platinum Sensitive Serous Ovarian Cancer

This study is for women with a type of ovarian cancer called platinum-sensitive serous ovarian cancer. It is testing a drug called olaparib (AZD2281), which works in a different way from standard chemotherapy by blocking a protein that cancer cells need to repair their DNA. The goal is to find out whether taking olaparib after responding to platinum-based chemotherapy can delay the cancer from growing back (called progression-free survival). You may be eligible if: - You are a woman (18+) with a confirmed diagnosis of serous ovarian cancer (including recurrent disease) - You have completed at least 2 previous courses of platinum-based chemotherapy - Your cancer responded to both previous chemotherapy courses (partial or complete response) - Your cancer is still responding at the end of your most recent chemotherapy - You started the study within 8 weeks of completing your last chemotherapy dose You may NOT be eligible if: - You have previously received a PARP inhibitor (including olaparib) - You have low-grade ovarian cancer - You had fluid drained from your abdomen during the last 2 cycles of chemotherapy - You received chemotherapy or radiotherapy (for non-palliative reasons) within 2 weeks before joining Talk to your doctor about whether this trial might be right for you.